Published in Hepatology on September 19, 2014
Model of fibrolamellar hepatocellular carcinomas reveals striking enrichment in cancer stem cells. Nat Commun (2015) 1.43
Cholangiocytes derived from human induced pluripotent stem cells for disease modeling and drug validation. Nat Biotechnol (2015) 1.31
Lineage fate of ductular reactions in liver injury and carcinogenesis. J Clin Invest (2015) 1.02
CCN1 induces hepatic ductular reaction through integrin αvβ₅-mediated activation of NF-κB. J Clin Invest (2015) 1.00
Emerging evidence on the role of the Hippo/YAP pathway in liver physiology and cancer. J Hepatol (2015) 0.95
The interplay of the Notch signaling in hepatic stellate cells and macrophages determines the fate of liver fibrogenesis. Sci Rep (2015) 0.88
Modulation of liver tolerance by conventional and nonconventional antigen-presenting cells and regulatory immune cells. Cell Mol Immunol (2016) 0.85
The Histone Deacetylase Inhibitor Vaproic Acid Induces Cell Growth Arrest in Hepatocellular Carcinoma Cells via Suppressing Notch Signaling. J Cancer (2015) 0.83
Hepatitis B Virus HBx Activates Notch Signaling via Delta-Like 4/Notch1 in Hepatocellular Carcinoma. PLoS One (2016) 0.83
Differentiation therapy for hepatocellular carcinoma: Multifaceted effects of miR-148a on tumor growth and phenotype and liver fibrosis. Hepatology (2016) 0.82
Osteopontin: a new player in regulating hepatic ductular reaction and hepatic progenitor cell responses during chronic liver injury. Gut (2014) 0.81
Molecular and proteomic insight into Notch1 characterization in hepatocellular carcinoma. Oncotarget (2016) 0.81
Actin-like 6A predicts poor prognosis of hepatocellular carcinoma and promotes metastasis and epithelial-mesenchymal transition. Hepatology (2016) 0.81
Notch1 Pathway Protects against Burn-Induced Myocardial Injury by Repressing Reactive Oxygen Species Production through JAK2/STAT3 Signaling. Oxid Med Cell Longev (2016) 0.77
Notch Signaling Coordinates Progenitor Cell-Mediated Biliary Regeneration Following Partial Hepatectomy. Sci Rep (2016) 0.77
Emerging roles of FGF signaling in hepatocellular carcinoma. Transl Cancer Res (2016) 0.76
Notch4+ cancer stem-like cells promote the metastatic and invasive ability of melanoma. Cancer Sci (2016) 0.76
Inflammation and Notch signaling: a crosstalk with opposite effects on tumorigenesis. Cell Death Dis (2016) 0.76
Inhibition of miR-21 rescues liver regeneration after partial hepatectomy in ethanol-fed rats. Am J Physiol Gastrointest Liver Physiol (2016) 0.76
Phenotypically anchored transcriptome profiling of developmental exposure to the antimicrobial agent, triclosan, reveals hepatotoxicity in embryonic zebrafish. Toxicol Appl Pharmacol (2016) 0.76
Notch signaling and M1 macrophage activation in obesity-alcohol synergism. Clin Res Hepatol Gastroenterol (2015) 0.76
Endothelial notch signaling is essential to prevent hepatic vascular malformations in mice. Hepatology (2016) 0.76
A faithful JAGGED1 haploinsufficiency mouse model of arteriohepatic dysplasia (Alagille syndrome) after all. Hepatology (2015) 0.75
Delta-Like Ligand 4 Modulates Liver Damage by Down-Regulating Chemokine Expression. Am J Pathol (2016) 0.75
Current Strategies to Generate Mature Human induced Pluripotent Stem Cells Derived Cholangiocytes and Future Applications. Organogenesis (2017) 0.75
Hippo Signaling in the Liver Regulates Organ Size, Cell Fate, and Carcinogenesis. Gastroenterology (2016) 0.75
Oncogenic potential of IDH1R132C mutant in cholangiocarcinoma development in mice. World J Gastroenterol (2016) 0.75
Hippo signaling interactions with Wnt/β-catenin and Notch signaling repress liver tumorigenesis. J Clin Invest (2016) 0.75
Notch, metabolism and macrophages. Oncotarget (2015) 0.75
Jagged 1 is a major Notch ligand along cholangiocarcinoma development in mice and humans. Oncogenesis (2016) 0.75
miR-494-3p is a novel tumor driver of lung carcinogenesis. Oncotarget (2016) 0.75
LKB1 and Notch Pathways Interact and Control Biliary Morphogenesis. PLoS One (2015) 0.75
Adipocyte-specific blockade of gamma-secretase, but not inhibition of Notch activity, reduces adipose insulin sensitivity. Mol Metab (2015) 0.75
Prepartum body condition score and plane of nutrition affect the hepatic transcriptome during the transition period in grazing dairy cows. BMC Genomics (2016) 0.75
Autocrine and Paracrine Mechanisms Promoting Chemoresistance in Cholangiocarcinoma. Int J Mol Sci (2017) 0.75
Effect of prolyl hydroxylase domain 2 haplodeficiency on liver progenitor cell characteristics in early mouse hepatocarcinogenesis. EXCLI J (2016) 0.75
Regulation of ERK and AKT pathways by hepatitis B virus X protein via the Notch1 pathway in hepatocellular carcinoma. Int J Oncol (2017) 0.75
Endoderm Jagged induces liver and pancreas duct lineage in zebrafish. Nat Commun (2017) 0.75
The canonical Notch signaling pathway: unfolding the activation mechanism. Cell (2009) 14.72
Alagille syndrome is caused by mutations in human Jagged1, which encodes a ligand for Notch1. Nat Genet (1997) 6.66
A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells. Nat Med (2006) 6.31
Mutations in the human Jagged1 gene are responsible for Alagille syndrome. Nat Genet (1997) 5.58
Notch signaling: the core pathway and its posttranslational regulation. Dev Cell (2009) 4.49
Macrophage-derived Wnt opposes Notch signaling to specify hepatic progenitor cell fate in chronic liver disease. Nat Med (2012) 3.96
NOTCH2 mutations cause Alagille syndrome, a heterogeneous disorder of the notch signaling pathway. Am J Hum Genet (2006) 3.55
Liver progenitor cells yield functional hepatocytes in response to chronic liver injury in mice. Gastroenterology (2012) 3.34
Notch signaling: simplicity in design, versatility in function. Development (2011) 3.13
Robust cellular reprogramming occurs spontaneously during liver regeneration. Genes Dev (2013) 2.96
Notch signaling controls liver development by regulating biliary differentiation. Development (2009) 2.93
A mouse model of Alagille syndrome: Notch2 as a genetic modifier of Jag1 haploinsufficiency. Development (2002) 2.88
Fate tracing of mature hepatocytes in mouse liver homeostasis and regeneration. J Clin Invest (2011) 2.83
Cholangiocarcinomas can originate from hepatocytes in mice. J Clin Invest (2012) 2.56
Transdifferentiation of rat hepatocytes into biliary cells after bile duct ligation and toxic biliary injury. Hepatology (2005) 2.41
Notch signaling and inherited disease syndromes. Hum Mol Genet (2003) 2.40
Canonical Notch2 signaling determines biliary cell fates of embryonic hepatoblasts and adult hepatocytes independent of Hes1. Hepatology (2013) 2.34
Intrahepatic bile ducts develop according to a new mode of tubulogenesis regulated by the transcription factor SOX9. Gastroenterology (2009) 2.33
Intrahepatic cholangiocarcinoma can arise from Notch-mediated conversion of hepatocytes. J Clin Invest (2012) 2.26
Liver-specific inactivation of Notch2, but not Notch1, compromises intrahepatic bile duct development in mice. Hepatology (2008) 2.21
Cancer stem cells in the development of liver cancer. J Clin Invest (2013) 2.06
Notch-RBP-J signaling regulates the transcription factor IRF8 to promote inflammatory macrophage polarization. Nat Immunol (2012) 1.81
The role of notch signaling in the development of intrahepatic bile ducts. Gastroenterology (2004) 1.81
Notch signaling controls hepatoblast differentiation by altering the expression of liver-enriched transcription factors. J Cell Sci (2004) 1.78
Bile duct proliferation in liver-specific Jag1 conditional knockout mice: effects of gene dosage. Hepatology (2007) 1.78
Jagged1 in the portal vein mesenchyme regulates intrahepatic bile duct development: insights into Alagille syndrome. Development (2010) 1.78
Modeling pathogenesis of primary liver cancer in lineage-specific mouse cell types. Gastroenterology (2013) 1.76
Notch signaling inhibits hepatocellular carcinoma following inactivation of the RB pathway. J Exp Med (2011) 1.74
Inducible inactivation of Notch1 causes nodular regenerative hyperplasia in mice. Hepatology (2005) 1.73
Notch signaling is activated in human hepatocellular carcinoma and induces tumor formation in mice. Gastroenterology (2012) 1.71
Ductular reactions in human liver: diversity at the interface. Hepatology (2011) 1.70
Constitutive Notch2 signaling induces hepatic tumors in mice. Hepatology (2013) 1.65
Notch signaling regulates bile duct morphogenesis in mice. PLoS One (2008) 1.59
Inhibition of Notch signaling ameliorates insulin resistance in a FoxO1-dependent manner. Nat Med (2011) 1.55
Links between hepatic fibrosis, ductular reaction, and progenitor cell expansion. Gastroenterology (2013) 1.53
Notch signaling regulates formation of the three-dimensional architecture of intrahepatic bile ducts in mice. Hepatology (2010) 1.53
Notch1 deficiency results in decreased inflammation during wound healing and regulates vascular endothelial growth factor receptor-1 and inflammatory cytokine expression in macrophages. J Immunol (2010) 1.49
Biliary differentiation and bile duct morphogenesis in development and disease. Int J Biochem Cell Biol (2009) 1.47
Characterisation of the liver progenitor cell niche in liver diseases: potential involvement of Wnt and Notch signalling. Gut (2009) 1.44
Generation and characterization of p53 null transformed hepatic progenitor cells: oval cells give rise to hepatocellular carcinoma. Carcinogenesis (2002) 1.42
The niche of stellate cells within rat liver. Hepatology (2009) 1.40
Inducible nitric oxide synthase up-regulates Notch-1 in mouse cholangiocytes: implications for carcinogenesis. Gastroenterology (2005) 1.37
Expression of Notch-1 and its ligand Jagged-1 in rat liver during liver regeneration. Hepatology (2004) 1.37
A critical role for notch signaling in the formation of cholangiocellular carcinomas. Cancer Cell (2013) 1.30
Reiterative use of the notch signal during zebrafish intrahepatic biliary development. Dev Dyn (2010) 1.29
Analysis of liver repair mechanisms in Alagille syndrome and biliary atresia reveals a role for notch signaling. Am J Pathol (2007) 1.26
Inhibition of Notch uncouples Akt activation from hepatic lipid accumulation by decreasing mTorc1 stability. Nat Med (2013) 1.23
Notch2 signaling promotes biliary epithelial cell fate specification and tubulogenesis during bile duct development in mice. Hepatology (2009) 1.22
Notch signal suppresses Toll-like receptor-triggered inflammatory responses in macrophages by inhibiting extracellular signal-regulated kinase 1/2-mediated nuclear factor κB activation. J Biol Chem (2011) 1.21
Inhibition of Notch signaling by a γ-secretase inhibitor attenuates hepatic fibrosis in rats. PLoS One (2012) 1.16
Disruption of Notch1 induces vascular remodeling, intussusceptive angiogenesis, and angiosarcomas in livers of mice. Gastroenterology (2012) 1.09
Biodiversity and noncanonical Notch signaling. Curr Top Dev Biol (2010) 1.06
Notch signaling regulates tubular morphogenesis during repair from biliary damage in mice. J Hepatol (2013) 1.04
Sry HMG box protein 9-positive (Sox9+) epithelial cell adhesion molecule-negative (EpCAM-) biphenotypic cells derived from hepatocytes are involved in mouse liver regeneration. J Biol Chem (2014) 1.02
Notch signaling in hepatocellular carcinoma: guilty in association! Gastroenterology (2012) 0.98
Notch signaling and new therapeutic options in liver disease. J Hepatol (2013) 0.96
Disruption of the transcription factor recombination signal-binding protein-Jkappa (RBP-J) leads to veno-occlusive disease and interfered liver regeneration in mice. Hepatology (2009) 0.93
Molecular mechanisms of liver and bile duct development. Wiley Interdiscip Rev Dev Biol (2012) 0.85
Activation of Notch signaling is required for cholangiocarcinoma progression and is enhanced by inactivation of p53 in vivo. PLoS One (2013) 0.83
Variation in liver histology in Alagille's syndrome. Am J Gastroenterol (1981) 0.82
Adjuvant gemcitabine therapy improves survival in a locally induced, R0-resectable model of metastatic intrahepatic cholangiocarcinoma. Hepatology (2013) 0.80
Genome-wide meta-analyses identify three loci associated with primary biliary cirrhosis. Nat Genet (2010) 3.15
Effects of angiogenic factor overexpression by human and rodent cholangiocytes in polycystic liver diseases. Hepatology (2006) 2.61
The cholangiopathies: disorders of biliary epithelia. Gastroenterology (2004) 2.38
A randomized study on Peg-interferon alfa-2a with or without ribavirin in liver transplant recipients with recurrent hepatitis C. J Hepatol (2007) 1.83
Cytokine-stimulated nitric oxide production inhibits adenylyl cyclase and cAMP-dependent secretion in cholangiocytes. Gastroenterology (2003) 1.79
Correction of CFTR malfunction and stimulation of Ca-activated Cl channels restore HCO3- secretion in cystic fibrosis bile ductular cells. Hepatology (2002) 1.79
Side chain structure determines unique physiologic and therapeutic properties of norursodeoxycholic acid in Mdr2-/- mice. Hepatology (2009) 1.72
Platelet-derived growth factor-D and Rho GTPases regulate recruitment of cancer-associated fibroblasts in cholangiocarcinoma. Hepatology (2013) 1.65
Insulin resistance and necroinflammation drives ductular reaction and epithelial-mesenchymal transition in chronic hepatitis C. Gut (2010) 1.59
Ursodeoxycholic acid stimulates cholangiocyte fluid secretion in mice via CFTR-dependent ATP secretion. Gastroenterology (2007) 1.59
Liver Match, a prospective observational cohort study on liver transplantation in Italy: study design and current practice of donor-recipient matching. Dig Liver Dis (2010) 1.54
Comparison between two high-dose methylprednisolone schedules in the treatment of acute hepatic cellular rejection in liver transplant recipients: a controlled clinical trial. Liver Transpl (2002) 1.50
"The city of Hepar": rituals, gastronomy, and politics at the origins of the modern names for the liver. J Hepatol (2011) 1.42
Mammalian target of rapamycin regulates vascular endothelial growth factor-dependent liver cyst growth in polycystin-2-defective mice. Hepatology (2010) 1.31
ERK1/2-dependent vascular endothelial growth factor signaling sustains cyst growth in polycystin-2 defective mice. Gastroenterology (2009) 1.29
Analysis of liver repair mechanisms in Alagille syndrome and biliary atresia reveals a role for notch signaling. Am J Pathol (2007) 1.26
Morphological and functional features of hepatic cyst epithelium in autosomal dominant polycystic kidney disease. Am J Pathol (2008) 1.12
Dual farnesoid X receptor/TGR5 agonist INT-767 reduces liver injury in the Mdr2-/- (Abcb4-/-) mouse cholangiopathy model by promoting biliary HCO⁻₃ output. Hepatology (2011) 1.11
Epithelial-mesenchymal interactions in biliary diseases. Semin Liver Dis (2011) 1.11
Altered store operated calcium entry increases cyclic 3',5'-adenosine monophosphate production and extracellular signal-regulated kinases 1 and 2 phosphorylation in polycystin-2-defective cholangiocytes. Hepatology (2012) 1.09
Loss of CFTR affects biliary epithelium innate immunity and causes TLR4-NF-κB-mediated inflammatory response in mice. Gastroenterology (2011) 1.07
Notch signaling regulates tubular morphogenesis during repair from biliary damage in mice. J Hepatol (2013) 1.04
Thiazolidinedione treatment inhibits bile duct proliferation and fibrosis in a rat model of chronic cholestasis. World J Gastroenterol (2005) 1.04
Epithelial expression of angiogenic growth factors modulate arterial vasculogenesis in human liver development. Hepatology (2008) 1.03
Genetic associations in Italian primary sclerosing cholangitis: heterogeneity across Europe defines a critical role for HLA-C. J Hepatol (2010) 1.02
Cyclic AMP/PKA-dependent paradoxical activation of Raf/MEK/ERK signaling in polycystin-2 defective mice treated with sorafenib. Hepatology (2012) 0.99
Timing of reinfection and mechanisms of hepatocellular damage in transplanted hepatitis C virus-reinfected liver. Liver Transpl (2002) 0.99
Notch signaling in hepatocellular carcinoma: guilty in association! Gastroenterology (2012) 0.98
Nuclear expression of S100A4 calcium-binding protein increases cholangiocarcinoma invasiveness and metastasization. Hepatology (2011) 0.96
Notch signalling beyond liver development: emerging concepts in liver repair and oncogenesis. Clin Res Hepatol Gastroenterol (2013) 0.92
Vascular biology of the biliary epithelium. J Gastroenterol Hepatol (2013) 0.91
Defective regulation of cholangiocyte Cl-/HCO3(-) and Na+/H+ exchanger activities in primary biliary cirrhosis. Hepatology (2002) 0.91
Protein kinase A-dependent pSer(675) -β-catenin, a novel signaling defect in a mouse model of congenital hepatic fibrosis. Hepatology (2013) 0.88
Cholangiocarcinoma in Italy: A national survey on clinical characteristics, diagnostic modalities and treatment. Results from the "Cholangiocarcinoma" committee of the Italian Association for the Study of Liver disease. Dig Liver Dis (2010) 0.87
Glibenclamide stimulates fluid secretion in rodent cholangiocytes through a cystic fibrosis transmembrane conductance regulator-independent mechanism. Gastroenterology (2005) 0.86
Prediction of progression-free survival in patients presenting with hepatocellular carcinoma within the Milan criteria. Liver Transpl (2010) 0.85
Malignancies in Primary Sclerosing Cholangitis - A Continuing Threat. Dig Dis (2015) 0.83
Liver transplant in cystic fibrosis: a poll among European centers. A study from the European Liver Transplant Registry. Transpl Int (2006) 0.83
Hepatitis B-core antibody positive donors in liver transplantation and their impact on graft survival: evidence from the Liver Match cohort study. J Hepatol (2012) 0.83
Isolation and characterization of biliary epithelial and stromal cells from resected human cholangiocarcinoma: a novel in vitro model to study tumor-stroma interactions. Oncol Rep (2013) 0.82
Extended right split liver graft for primary transplantation in children and adults. Transpl Int (2006) 0.81
Treatment with pegylated interferon and ribavirin for hepatitis C virus-associated severe cryoglobulinemia in a liver/kidney transplant recipient. J Clin Gastroenterol (2007) 0.81
Ursodeoxycholate further increases bile-duct cell proliferative response induced by partial bile-duct ligation in rats. Virchows Arch (2004) 0.80
Systemic therapy in hepatocellular carcinoma. Clin Liver Dis (2011) 0.78
Nonsteroidal anti-inflammatory drug use, chronic liver disease, and hepatocellular carcinoma: the egg of columbus or another illusion? Hepatology (2013) 0.77
Incidence and management of colorectal cancer in liver transplant recipients. Clin Colorectal Cancer (2008) 0.76
Type I autoimmune hepatitis presenting with acute liver failure in the setting of wild mushroom ingestion. J Clin Gastroenterol (2008) 0.75
Healthcare costs associated with hepatocellular carcinoma and the value of care. Hepatology (2013) 0.75
Hepatic venous pressure gradient (HVPG), serum sodium (SNa), and model of end-stage liver disease score (MELD): prognostic significance and correlations. J Clin Gastroenterol (2007) 0.75
Toward a rational management of very early hepatocellular carcinoma. Hepatology (2013) 0.75
Prognostic prediction in hepatocellular carcinoma: from art to science. J Clin Gastroenterol (2008) 0.75
Isolated idiopathic bile ductular hyperplasia in patients with persistently abnormal liver function tests. J Hepatol (2004) 0.75
[Antiplatelet drugs and gastrointestinal bleeding: numquam periclum sine periclo vincitur]. Ital Heart J Suppl (2005) 0.75
EASL recognition awardee 2013: Professor Jesus Prieto. J Hepatol (2013) 0.75